Paclitaxel

erb-b2 receptor tyrosine kinase 2 ; Homo sapiens







381 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
201 23682812 Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer. 2013 Jul-Aug 3
202 23697602 An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. 2013 Jun 1
203 23870999 Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells. 2013 Dec 1 1
204 24101324 A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. 2013 Oct 2
205 24155780 Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. 2013 2
206 24168763 Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. 2013 6
207 24223926 An integrated model of the transcriptome of HER2-positive breast cancer. 2013 1
208 21359953 Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. 2012 Apr 1
209 21380780 Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. 2012 Jun 1
210 21920731 Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. 2012 Sep 1
211 22094934 Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01. 2012 Apr 2
212 22116711 A new anticancer compound, oblongifolin C, inhibits tumor growth and promotes apoptosis in HeLa cells through Bax activation. 2012 Sep 15 1
213 22679488 Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. 2012 1
214 22687601 Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. 2012 Aug 1
215 22772380 Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice. 2012 Aug 1
216 22824824 Genomic methylation profiling combined with gene expression microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma taxol resistance. 2012 Sep 1
217 22851567 Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. 2012 Sep 20 1
218 23028798 Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. 2012 1
219 23268070 [A case of unresectable HER2-positive advanced gastric cancer successfully treated by combination therapy with trastuzumab and paclitaxel]. 2012 Nov 2
220 23422737 Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. 2012 Mar 2
221 23960813 The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). 2012 Oct 1
222 21086124 In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. 2011 Mar 1
223 21350003 A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. 2011 May 15 1
224 21712253 Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. 2011 Aug 2
225 21788566 Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. 2011 Sep 1 1
226 21868556 Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. 2011 Sep 1
227 21887460 Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. 2011 Dec 1
228 22135629 A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy. 2011 Sep 1
229 22173491 Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation. 2011 Dec 2
230 19826412 Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. 2010 Jan 14 1
231 20095796 Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. 2010 Apr 1
232 20145176 Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. 2010 Feb 15 1
233 20150272 Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab. 2010 Mar 3
234 20198351 Increase of the therapeutic effect by treating nasopharyngeal tumor with combination of HER-2 siRNA and paclitaxel. 2010 Apr 5
235 20218616 Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway. 2010 Apr 28 1
236 20332474 Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer. 2010 Feb 1
237 20473628 A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment. 2010 Dec 2
238 20498641 Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. 2010 Jul 22 5
239 20530274 Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. 2010 Jul 10 1
240 20547325 Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP. 2010 Aug 4
241 20664599 Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer. 2010 Sep 7 6
242 20673976 Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. 2010 Oct 1
243 20705560 Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. 2010 Aug 1 3
244 20975068 Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. 2010 Dec 1 1
245 21029701 [Efficacy and safety assessment of neoadjuvant paclitaxel and trastuzumab in Chinese women with Her-2 positive operable breast cancer]. 2010 Jul 2
246 21088439 A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. 2010 2
247 21139994 Digitoxin activates EGR1 and synergizes with paclitaxel on human breast cancer cells. 2010 Nov 18 2
248 21160270 [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. 2010 Dec 1
249 21188093 Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. 2010 Jan 7 1
250 18548321 A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. 2009 1